Grupo Multidisciplinario y Multicéntrico para Estudio del Melanoma

JULIO

Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas.
Am J Dermatopathol. 2009;31:354-63.
URIBE P , Wistuba II, Gonzalez S

Primary cutaneous melanomas seen as inflamed pigmented lesions in patients undergoing adjuvant interferon treatment: a possible diagnostic clue for physicians.
Arch Dermatol. 2009;145:565-8.
HU S , Kim CC, Jessup C, Phung TL, et al

The prevalence of melanocytic nevi on the soles in the Japanese population.
J Am Acad Dermatol. 2009;60:767-71.
KOGUSHI-NISHI H , Kawasaki J, Kageshita T, Ishihara T, et al

Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer
J Clin Oncol. 2009.
BOTTOMLEY A , Coens C, Suciu S, Santinami M, et al

Sentinel node biopsy and standard of care for melanoma.
J Am Acad Dermatol. 2009;60:872-5.
BALCH CM , Morton DL, Gershenwald JE, McMasters KM, et al

Strategies for early melanoma detection: Approaches to the patient with nevi.
J Am Acad Dermatol. 2009;60:719-35.
GOODSON AG , Grossman D

JUNIO

Safety and Efficacy of Isolated Limb Infusion With Cytotoxic Drugs in Elderly Patients With Advanced Locoregional Melanoma.
Ann Surg. 2009.
KROON HM , Lin DY, Kam PC, Thompson JF, et al

Cutaneous Melanoma During Pregnancy: Is the Controversy Over?
J Clin Oncol. 2009.
LENS M , Rosdahl I, Newton-Bishop J

Nuclear PTEN levels and G2 progression in melanoma cells.
Melanoma Res. 2009.
JACOB AI , Romigh T, Waite KA, Eng C, et al

Sentinel node biopsy and standard of care for melanoma.
J Am Acad Dermatol. 2009;60:872-5.
BALCH CM, Morton DL, Gershenwald JE, McMasters KM, et al.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Oncogene. 2009.
GOEL VK, Ibrahim N, Jiang G, Singhal M, et al.

Great Ormond Street Hospital for Children Registry for Congenital Melanocytic Naevi: prospective study 1988-2007. Part 2-evaluation of treatments.
Br J Dermatol. 2008.
KINSLER VA, Birley J, Atherton DJ.

Computer versus human diagnosis of melanoma: evaluation of the feasibility of an automated diagnostic system in a prospective clinical trial.
Melanoma Res. 2009.
DREISEITL S, Binder M, Hable K, Kittler H, et al.

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma.
J Clin Oncol. 2009.
HAUSCHILD A, Agarwala SS, Trefzer U, Hogg D, et al.

MAYO

Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
J Am Acad Dermatol. 2009;60:863-8.
MEIER F, Guenova E, Clasen S, Eigentler T, et al.

The superficial atypical Spitz tumor and malignant melanoma of superficial spreading type arising in association with the superficial atypical Spitz tumor: A distinct form of dysplastic Spitzoid nevomelanocytic proliferation.
J Am Acad Dermatol. 2009;60:814-23.
MAGRO CM, Yaniv S, Mihm MC.

Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
J Am Acad Dermatol. 2009;60:758-66.
CHUA R, Setzer S, Govindarajan B, Sexton D, et al.

Strategies for early melanoma detection: Approaches to the patient with nevi.
J Am Acad Dermatol. 2009;60:719-35.
GOODSON AG, Grossman D.

Epidermotropic chondroid metastasis of melanoma: report of a case of metastatic melanoma with previously unreported morphological features.
Am J Dermatopathol. 2009;31:301-4.
PIANA S, Valli R, Ricci C.

Pigmented Paget disease--a diagnostic pitfall mimicking melanoma.
Am J Dermatopathol. 2009;31:223-6.
PETERSSON F, Ivan D, Kazakov DV, Michal M, et al.

Peroxisome proliferator-activating receptors: a new way to treat melanoma?
J Invest Dermatol. 2009;129:1061-3.
SCHADENDORF D.

Differences in Cytokine Levels in Melanoma Patients with and without Redness (Brenner Sign).
Anticancer Res. 2009;29:1793-6.
MASHIAH J , Brenner S, Pessach Y, Barak V, et al

alpha-Melanocyte-stimulating hormone-induced eruptive nevi.
Arch Dermatol. 2009;145:441-4.
CARDONES AR , Grichnik JM

Improved Survival for Stage IV Melanoma From an Unknown Primary Site.
J Clin Oncol. 2009.
LEE CC , Faries MB, Wanek LA, Morton DL, et al

Polymorphisms in genes involved in DNA repair, cell growth, oxidative stress and inflammatory response, and melanoma risk.
Br J Dermatol. 2009.
GU F , Qureshi AA, Kraft P, Guo Q, et al

The prevalence of melanocytic nevi on the soles in the Japanese population.
J Am Acad Dermatol. 2009;60:767-71.
KOGUSHI-NISHI H , Kawasaki J, Kageshita T, Ishihara T, et al

Progression of NRAS and BRAF mutations in cutaneous melanoma.
J Invest Dermatol. 2009;129:1318.
ROSSO R , Romagosa Y, Kirsner RS

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Melanoma Res. 2009;19:167-75.
HOMSI J , Cubitt CL, Zhang S, Munster PN, et al

COX-2 expression in malignant melanoma: a novel prognostic marker?
Melanoma Res. 2009;19:8-16.
BECKER MR , Siegelin MD, Rompel R, Enk AH, et al

A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence.
Int J Cancer. 2009.
NUCCITELLI R , Chen X, Pakhomov AG, Baldwin WH, et al

Development of a two-step method for the diagnosis of melanoma by reflectance confocal microscopy.
J Am Acad Dermatol. 2009.
SEGURA S , Puig S, Carrera C, Palou J, et al

Immunosuppression and melanocyte proliferation.
Melanoma Res. 2009;19:63-8.
ZATTRA E , Fortina AB, Bordignon M, Piaserico S, et al

CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.
Br J Cancer. 2009.
SINGH S , Nannuru KC, Sadanandam A, Varney ML, et al

Sentinel node biopsy and standard of care for melanoma.
J Am Acad Dermatol. 2009;60:872-5.
BALCH CM , Morton DL, Gershenwald JE, McMasters KM, et al

Strategies for early melanoma detection: Approaches to the patient with nevi.
J Am Acad Dermatol. 2009;60:719-35.
GOODSON AG , Grossman D

A multi-marker assay to distinguish malignant melanomas from benign nevi.
Proc Natl Acad Sci U S A. 2009.
1. KASHANI-SABET M, Rangel J, Torabian S, Nosrati M, et al.

Systematic review of dermoscopy and digital dermoscopy/ artificial intelligence for the diagnosis of melanoma.
Br J Dermatol. 2009.
2. RAJPARA SM, Botello AP, Townend J, Ormerod AD, et al.

Lymph node ratio predicts disease-specific survival in melanoma patients.
Cancer. 2009.
3. XING Y, Badgwell BD, Ross MI, Gershenwald JE, et al.

ABRIL

CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.
Br J Cancer. 2009.
SINGH S, Nannuru KC, Sadanandam A, Varney ML, et al.

Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner.
Cancer Lett. 2009.
LIMA LG, Chammas R, Monteiro RQ, Moreira ME, et al.

Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: Association to tumor derived alpha-N-acetylgalactosaminidase activity.
Cancer Lett. 2009.
GRECO M, Mitri MD, Chiriaco F, Leo G, et al.

Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes.
Cancer Lett. 2009.
BREZILLON S, Radwanska A, Zeltz C, Malkowski A, et al.

Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005.
J Am Acad Dermatol. 2009.
PRUTHI DK, Guilfoyle R, Nugent Z, Wiseman MC, et al.

Sentinel node biopsy and standard of care for melanoma.
J Am Acad Dermatol. 2009;60:872-5.
BALCH CM, Morton DL, Gershenwald JE, McMasters KM, et al.

N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase.
J Immunol. 2009;182:4830-5.
OSTANKOVITCH M, Altrich-Vanlith M, Robila V, Engelhard VH, et al.

Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stimulatory potential.
J Immunol. 2009;182:4538-46.
LOHMANN C, Muschaweckh A, Kirschnek S, Jennen L, et al.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Oncogene. 2009.
GOEL VK, Ibrahim N, Jiang G, Singhal M, et al.

Effectiveness of Treatments for Metastatic Uveal Melanoma.
Am J Ophthalmol. 2009.
AUGSBURGER JJ, Correa ZM, Shaikh AH.

Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.
Arch Dermatol. 2009;145:427-34.
BRADFORD PT, Goldstein AM, McMaster ML, Tucker MA, et al.

Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study.
Arch Dermatol. 2009;145:418-23.
GAUDY-MARQUESTE C, Madjlessi N, Guillot B, Avril MF, et al.

Factors associated with physician discovery of early melanoma in middle-aged and older men.
Arch Dermatol. 2009;145:409-14.
GELLER AC, Johnson TM, Miller DR, Brooks KR, et al.

Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness.
Arch Dermatol. 2009;145:397-404.
SWETTER SM, Johnson TM, Miller DR, Layton CJ, et al.

SPECT/CT Lymphoscintigraphy to Locate the Sentinel Lymph Node in Patients with Melanoma.
Ann Surg Oncol. 2009.
UREN RF.

Translating uveal melanoma cytogenetics into clinical care.
Arch Ophthalmol. 2009;127:423-9.
DAMATO B, Coupland SE.

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Br J Cancer. 2009;100:1245-9.
KEFFORD RF, Thomas NP, Corrie PG, Palmer C, et al.

Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
Melanoma Res. 2009.
SOARES DE SA BC, Fugimori ML, Braga Ribeiro KD, Duprat Neto JP, et al.

Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential.
Proc Natl Acad Sci U S A. 2009.
LI LZ, Zhou R, Xu HN, Moon L, et al.

Major Amputation for Irresectable Extremity Melanoma After Failure of Isolated Limb Infusion.
Ann Surg Oncol. 2009.
KROON HM, Lin DY, Kam PC, Thompson JF, et al.

A Population-Based Study of Australian Twins with Melanoma Suggests a Strong Genetic Contribution to Liability.
J Invest Dermatol. 2009.
SHEKAR SN, Duffy DL, Youl P, Baxter AJ, et al.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Oncogene. 2009.
GOEL VK, Ibrahim N, Jiang G, Singhal M, et al.

Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy.
J Immunol. 2009;182:1260-9.
DICKGREBER N, Stoitzner P, Bai Y, Price KM, et al.

A high percentage of skin melanoma cells expresses SPANX proteins.
Am J Dermatopathol. 2009;31:182-6.
SALEMI M, Calogero AE, Vicari E, Migliore E, et al.

Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.
Proc Natl Acad Sci U S A. 2009.
WANG Y, Digiovanna JJ, Stern JB, Hornyak TJ, et al.

Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling.
J Clin Oncol. 2009.
FINDEISEN P, Zapatka M, Peccerella T, Matzk H, et al.

MARZO

In vivo confocal laser scanning microscopy in the diagnosis of melanocytic skin tumours.
Br J Dermatol. 2008.
GERGER A, Hofmann-Wellenhof R, Samonigg H, Smolle J, et al.

Use of photographs illustrating ABCDE criteria in skin self-examination.
Arch Dermatol. 2009;145:332-3.
ROBINSON JK, Ortiz S.

In vivo confocal laser scanning microscopy in the diagnosis of melanocytic skin tumours.
Br J Dermatol. 2008.
GERGER A, Hofmann-Wellenhof R, Samonigg H, Smolle J, et al.

Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma.
Ann Surg. 2009.
MURALI R, Hughes MT, Fitzgerald P, Thompson JF, et al.

Stage III melanoma treated with chemotherapy after surgery during the second trimester of pregnancy.
Arch Dermatol. 2009;145:346-8.
ISHIDA I, Yamaguchi Y, Tanemura A, Hosokawa K, et al.

Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
Cancer. 2009.
KROON HM, Lin DY, Kam PC, Thompson JF, et al.

Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial.
Clin Cancer Res. 2009.
DAVIS ID, Brady B, Kefford RF, Millward M, et al.

Health Care System and Socioeconomic Factors Associated With Variance in Use of Sentinel Lymph Node Biopsy for Melanoma in the United States.
J Clin Oncol. 2009.
BILIMORIA KY, Balch CM, Wayne JD, Chang DC, et al.

Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
Melanoma Res. 2009.
BRADY MS, Brown K, Patel A, Fisher C, et al.